- Home
- MEGL vs APVO Comparison
MEGL vs APVO Comparison
Compare MEGL & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGL
- APVO
- Stock Information
- Founded
- MEGL 2016
- APVO 2016
- Country
- MEGL Hong Kong
- APVO United States
- Employees
- MEGL N/A
- APVO N/A
- Industry
- MEGL Finance: Consumer Services
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- MEGL Finance
- APVO Health Care
- Exchange
- MEGL Nasdaq
- APVO Nasdaq
- Market Cap
- MEGL 6.8M
- APVO 4.1M
- IPO Year
- MEGL 2022
- APVO N/A
- Fundamental
- Price
- MEGL $1.38
- APVO $1.98
- Analyst Decision
- MEGL
- APVO Strong Buy
- Analyst Count
- MEGL 0
- APVO 1
- Target Price
- MEGL N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- MEGL 36.3K
- APVO 122.5K
- Earning Date
- MEGL 09-02-2025
- APVO 08-11-2025
- Dividend Yield
- MEGL N/A
- APVO N/A
- EPS Growth
- MEGL N/A
- APVO N/A
- EPS
- MEGL N/A
- APVO N/A
- Revenue
- MEGL $1,645,862.00
- APVO N/A
- Revenue This Year
- MEGL N/A
- APVO N/A
- Revenue Next Year
- MEGL N/A
- APVO N/A
- P/E Ratio
- MEGL N/A
- APVO N/A
- Revenue Growth
- MEGL N/A
- APVO N/A
- 52 Week Low
- MEGL $1.02
- APVO $1.72
- 52 Week High
- MEGL $5.52
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- MEGL 43.82
- APVO 32.74
- Support Level
- MEGL $1.33
- APVO $1.87
- Resistance Level
- MEGL $1.40
- APVO $2.07
- Average True Range (ATR)
- MEGL 0.06
- APVO 0.18
- MACD
- MEGL 0.00
- APVO 0.04
- Stochastic Oscillator
- MEGL 34.78
- APVO 29.55
About MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.